---
annotation-target: jciinsight-7-154344.pdf
---


>%%
>```annotation-json
>{"created":"2022-08-08T08:23:44.936Z","text":"净化","updated":"2022-08-08T08:23:44.936Z","document":{"title":"jciinsight-7-154344.pdf","link":[{"href":"urn:x-pdf:8d2ac365139147c193ac91cb106cc20a"},{"href":"vault:/hematology-theroy/papers/jciinsight-7-154344.pdf"}],"documentFingerprint":"8d2ac365139147c193ac91cb106cc20a"},"uri":"vault:/hematology-theroy/papers/jciinsight-7-154344.pdf","target":[{"source":"vault:/hematology-theroy/papers/jciinsight-7-154344.pdf","selector":[{"type":"TextPositionSelector","start":1336,"end":1352},{"type":"TextQuoteSelector","exact":"decontamination ","prefix":"cs in a randomized trial of gut ","suffix":"during allogeneic hematopoietic "}]}]}
>```
>%%
>*%%PREFIX%%cs in a randomized trial of gut%%HIGHLIGHT%% ==decontamination== %%POSTFIX%%during allogeneic hematopoietic*
>%%LINK%%[[#^pvfh1z7spne|show annotation]]
>%%COMMENT%%
>净化
>%%TAGS%%
>
^pvfh1z7spne


>%%
>```annotation-json
>{"created":"2022-08-08T08:24:24.865Z","updated":"2022-08-08T08:24:24.865Z","document":{"title":"jciinsight-7-154344.pdf","link":[{"href":"urn:x-pdf:8d2ac365139147c193ac91cb106cc20a"},{"href":"vault:/hematology-theroy/papers/jciinsight-7-154344.pdf"}],"documentFingerprint":"8d2ac365139147c193ac91cb106cc20a"},"uri":"vault:/hematology-theroy/papers/jciinsight-7-154344.pdf","target":[{"source":"vault:/hematology-theroy/papers/jciinsight-7-154344.pdf","selector":[{"type":"TextPositionSelector","start":3943,"end":4133},{"type":"TextQuoteSelector","exact":". The 2 arms did not differ in the predefined primary outcome of Shannon diversity of the gut microbiome at 2 weeks post-HCT (genus, P = 0.8; species, P = 0.44) or aGVHD incidence (P = 0.58)","prefix":"dstream infections (BSI).RESULTS","suffix":". Immune reconstitution of T cel"}]}]}
>```
>%%
>*%%PREFIX%%dstream infections (BSI).RESULTS%%HIGHLIGHT%% ==. The 2 arms did not differ in the predefined primary outcome of Shannon diversity of the gut microbiome at 2 weeks post-HCT (genus, P = 0.8; species, P = 0.44) or aGVHD incidence (P = 0.58)== %%POSTFIX%%. Immune reconstitution of T cel*
>%%LINK%%[[#^41mfttwmwxt|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^41mfttwmwxt


>%%
>```annotation-json
>{"created":"2022-08-08T08:26:00.733Z","updated":"2022-08-08T08:26:00.733Z","document":{"title":"jciinsight-7-154344.pdf","link":[{"href":"urn:x-pdf:8d2ac365139147c193ac91cb106cc20a"},{"href":"vault:/hematology-theroy/papers/jciinsight-7-154344.pdf"}],"documentFingerprint":"8d2ac365139147c193ac91cb106cc20a"},"uri":"vault:/hematology-theroy/papers/jciinsight-7-154344.pdf","target":[{"source":"vault:/hematology-theroy/papers/jciinsight-7-154344.pdf","selector":[{"type":"TextPositionSelector","start":5054,"end":5188},{"type":"TextQuoteSelector","exact":",  gut  decontamination  (GD)  with  nonab-sorbable antibiotics in the peri-HCT time period is administered in some clinical centers, ","prefix":"dence  and  severity  of   aGVHD","suffix":"largely on the basis  of   resul"}]}]}
>```
>%%
>*%%PREFIX%%dence  and  severity  of   aGVHD%%HIGHLIGHT%% ==,  gut  decontamination  (GD)  with  nonab-sorbable antibiotics in the peri-HCT time period is administered in some clinical centers,== %%POSTFIX%%largely on the basis  of   resul*
>%%LINK%%[[#^jtzl0u67ko|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^jtzl0u67ko


>%%
>```annotation-json
>{"created":"2022-08-08T08:39:57.660Z","text":"减小","updated":"2022-08-08T08:39:57.660Z","document":{"title":"jciinsight-7-154344.pdf","link":[{"href":"urn:x-pdf:8d2ac365139147c193ac91cb106cc20a"},{"href":"vault:/hematology-theroy/papers/jciinsight-7-154344.pdf"}],"documentFingerprint":"8d2ac365139147c193ac91cb106cc20a"},"uri":"vault:/hematology-theroy/papers/jciinsight-7-154344.pdf","target":[{"source":"vault:/hematology-theroy/papers/jciinsight-7-154344.pdf","selector":[{"type":"TextPositionSelector","start":5273,"end":5420},{"type":"TextQuoteSelector","exact":"y,  mouse  and  human  studies  have  demon-strated that nonabsorbable antibiotics can debulk intestinal bacteria and that this can decrease aGVHD ","prefix":"eclinical  studies.  Specificall","suffix":"(1–5). While the precise mechani"}]}]}
>```
>%%
>*%%PREFIX%%eclinical  studies.  Specificall%%HIGHLIGHT%% ==y,  mouse  and  human  studies  have  demon-strated that nonabsorbable antibiotics can debulk intestinal bacteria and that this can decrease aGVHD== %%POSTFIX%%(1–5). While the precise mechani*
>%%LINK%%[[#^pw4tgmm8fs|show annotation]]
>%%COMMENT%%
>减小
>%%TAGS%%
>
^pw4tgmm8fs


>%%
>```annotation-json
>{"created":"2022-08-08T08:40:30.210Z","updated":"2022-08-08T08:40:30.210Z","document":{"title":"jciinsight-7-154344.pdf","link":[{"href":"urn:x-pdf:8d2ac365139147c193ac91cb106cc20a"},{"href":"vault:/hematology-theroy/papers/jciinsight-7-154344.pdf"}],"documentFingerprint":"8d2ac365139147c193ac91cb106cc20a"},"uri":"vault:/hematology-theroy/papers/jciinsight-7-154344.pdf","target":[{"source":"vault:/hematology-theroy/papers/jciinsight-7-154344.pdf","selector":[{"type":"TextPositionSelector","start":5425,"end":5498},{"type":"TextQuoteSelector","exact":". While the precise mechanism of  how GD affects aGVHD remains unknown, i","prefix":"at this can decrease aGVHD (1–5)","suffix":"t is thought that decreasing mic"}]}]}
>```
>%%
>*%%PREFIX%%at this can decrease aGVHD (1–5)%%HIGHLIGHT%% ==. While the precise mechanism of  how GD affects aGVHD remains unknown, i== %%POSTFIX%%t is thought that decreasing mic*
>%%LINK%%[[#^j8y0ut577je|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^j8y0ut577je


>%%
>```annotation-json
>{"created":"2022-08-08T08:40:51.242Z","updated":"2022-08-08T08:40:51.242Z","document":{"title":"jciinsight-7-154344.pdf","link":[{"href":"urn:x-pdf:8d2ac365139147c193ac91cb106cc20a"},{"href":"vault:/hematology-theroy/papers/jciinsight-7-154344.pdf"}],"documentFingerprint":"8d2ac365139147c193ac91cb106cc20a"},"uri":"vault:/hematology-theroy/papers/jciinsight-7-154344.pdf","target":[{"source":"vault:/hematology-theroy/papers/jciinsight-7-154344.pdf","selector":[{"type":"TextPositionSelector","start":5503,"end":5696},{"type":"TextQuoteSelector","exact":"thought that decreasing microbial load or altering the microbiota composition can improve intestinal barrier integ-rity and decrease inflammation via interactions with the host immune system (r","prefix":"ts aGVHD remains unknown, it is ","suffix":"eviewed in refs. 6, 7).In  addit"}]}]}
>```
>%%
>*%%PREFIX%%ts aGVHD remains unknown, it is%%HIGHLIGHT%% ==thought that decreasing microbial load or altering the microbiota composition can improve intestinal barrier integ-rity and decrease inflammation via interactions with the host immune system (r== %%POSTFIX%%eviewed in refs. 6, 7).In  addit*
>%%LINK%%[[#^5gvpi2ltiei|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^5gvpi2ltiei


>%%
>```annotation-json
>{"created":"2022-08-08T08:41:37.239Z","text":"环丙沙星\n甲硝哒唑","updated":"2022-08-08T08:41:37.239Z","document":{"title":"jciinsight-7-154344.pdf","link":[{"href":"urn:x-pdf:8d2ac365139147c193ac91cb106cc20a"},{"href":"vault:/hematology-theroy/papers/jciinsight-7-154344.pdf"}],"documentFingerprint":"8d2ac365139147c193ac91cb106cc20a"},"uri":"vault:/hematology-theroy/papers/jciinsight-7-154344.pdf","target":[{"source":"vault:/hematology-theroy/papers/jciinsight-7-154344.pdf","selector":[{"type":"TextPositionSelector","start":6009,"end":6171},{"type":"TextQuoteSelector","exact":"ciprofloxacin plus metronidazole had a lower incidence of  grade II–IV aGVHD compared with those randomized to receive ciprofloxacin alone (25% vs. 50%, P < 0.01)","prefix":" patients randomized to receive ","suffix":" (8), suggesting a link between "}]}]}
>```
>%%
>*%%PREFIX%%patients randomized to receive%%HIGHLIGHT%% ==ciprofloxacin plus metronidazole had a lower incidence of  grade II–IV aGVHD compared with those randomized to receive ciprofloxacin alone (25% vs. 50%, P < 0.01)== %%POSTFIX%%(8), suggesting a link between*
>%%LINK%%[[#^fftiil569b4|show annotation]]
>%%COMMENT%%
>环丙沙星
>甲硝哒唑
>%%TAGS%%
>
^fftiil569b4


>%%
>```annotation-json
>{"created":"2022-08-08T08:42:33.367Z","updated":"2022-08-08T08:42:33.367Z","document":{"title":"jciinsight-7-154344.pdf","link":[{"href":"urn:x-pdf:8d2ac365139147c193ac91cb106cc20a"},{"href":"vault:/hematology-theroy/papers/jciinsight-7-154344.pdf"}],"documentFingerprint":"8d2ac365139147c193ac91cb106cc20a"},"uri":"vault:/hematology-theroy/papers/jciinsight-7-154344.pdf","target":[{"source":"vault:/hematology-theroy/papers/jciinsight-7-154344.pdf","selector":[{"type":"TextPositionSelector","start":6233,"end":6417},{"type":"TextQuoteSelector","exact":"However, other  studies  have  shown  that  the  use  of   systemic  antibiotics  with  activity  against  anaerobic  bacteria  is  associated with an increased risk of  aGVHD (9–11). ","prefix":"n anaerobic bacteria and aGVHD. ","suffix":"If  the effect of  GD on the pat"}]}]}
>```
>%%
>*%%PREFIX%%n anaerobic bacteria and aGVHD.%%HIGHLIGHT%% ==However, other  studies  have  shown  that  the  use  of   systemic  antibiotics  with  activity  against  anaerobic  bacteria  is  associated with an increased risk of  aGVHD (9–11).== %%POSTFIX%%If  the effect of  GD on the pat*
>%%LINK%%[[#^91237w0d6d|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^91237w0d6d


>%%
>```annotation-json
>{"created":"2022-08-08T08:44:49.408Z","updated":"2022-08-08T08:44:49.408Z","document":{"title":"jciinsight-7-154344.pdf","link":[{"href":"urn:x-pdf:8d2ac365139147c193ac91cb106cc20a"},{"href":"vault:/hematology-theroy/papers/jciinsight-7-154344.pdf"}],"documentFingerprint":"8d2ac365139147c193ac91cb106cc20a"},"uri":"vault:/hematology-theroy/papers/jciinsight-7-154344.pdf","target":[{"source":"vault:/hematology-theroy/papers/jciinsight-7-154344.pdf","selector":[{"type":"TextPositionSelector","start":6620,"end":6810},{"type":"TextQuoteSelector","exact":"Prior clinical trials for GD are confounded by the variations in the practice of  GD and systemic pro-phylaxis across centers with no consensus regarding the choice of  antibiotic regimen (r","prefix":"solve these discordant findings.","suffix":"eviewed in ref. 7). In addition,"}]}]}
>```
>%%
>*%%PREFIX%%solve these discordant findings.%%HIGHLIGHT%% ==Prior clinical trials for GD are confounded by the variations in the practice of  GD and systemic pro-phylaxis across centers with no consensus regarding the choice of  antibiotic regimen (r== %%POSTFIX%%eviewed in ref. 7). In addition,*
>%%LINK%%[[#^r41hiid4le|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^r41hiid4le


>%%
>```annotation-json
>{"created":"2022-08-08T08:45:15.245Z","updated":"2022-08-08T08:45:15.245Z","document":{"title":"jciinsight-7-154344.pdf","link":[{"href":"urn:x-pdf:8d2ac365139147c193ac91cb106cc20a"},{"href":"vault:/hematology-theroy/papers/jciinsight-7-154344.pdf"}],"documentFingerprint":"8d2ac365139147c193ac91cb106cc20a"},"uri":"vault:/hematology-theroy/papers/jciinsight-7-154344.pdf","target":[{"source":"vault:/hematology-theroy/papers/jciinsight-7-154344.pdf","selector":[{"type":"TextPositionSelector","start":6855,"end":7341},{"type":"TextQuoteSelector","exact":"s relied on culture-based approaches to measure microbiome composition. However, many  organisms  within  the  gut  microbiota,  such  as  strict  anaerobes,  are  difficult  to  culture  (7).  Modern  approaches based on next-generation sequencing (NGS) enable more comprehensive profiling of  the gut microbiome composition by overcoming the need to maintain viability of  the organisms within the stool sample and thus may help inform the specific impact of  GD on the gut microbiota","prefix":"f. 7). In addition, prior studie","suffix":".While aGVHD is the most prevale"}]}]}
>```
>%%
>*%%PREFIX%%f. 7). In addition, prior studie%%HIGHLIGHT%% ==s relied on culture-based approaches to measure microbiome composition. However, many  organisms  within  the  gut  microbiota,  such  as  strict  anaerobes,  are  difficult  to  culture  (7).  Modern  approaches based on next-generation sequencing (NGS) enable more comprehensive profiling of  the gut microbiome composition by overcoming the need to maintain viability of  the organisms within the stool sample and thus may help inform the specific impact of  GD on the gut microbiota== %%POSTFIX%%.While aGVHD is the most prevale*
>%%LINK%%[[#^5eyg3quuseo|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^5eyg3quuseo


>%%
>```annotation-json
>{"created":"2022-08-08T08:45:45.400Z","updated":"2022-08-08T08:45:45.400Z","document":{"title":"jciinsight-7-154344.pdf","link":[{"href":"urn:x-pdf:8d2ac365139147c193ac91cb106cc20a"},{"href":"vault:/hematology-theroy/papers/jciinsight-7-154344.pdf"}],"documentFingerprint":"8d2ac365139147c193ac91cb106cc20a"},"uri":"vault:/hematology-theroy/papers/jciinsight-7-154344.pdf","target":[{"source":"vault:/hematology-theroy/papers/jciinsight-7-154344.pdf","selector":[{"type":"TextPositionSelector","start":7425,"end":7577},{"type":"TextQuoteSelector","exact":" bloodstream infections  (BSIs)  are  also  an  important  cause  of   treatment-related  morbidity  and  mortality  in  patients  undergoing allo-HCT. ","prefix":"nt-related complication of  HCT,","suffix":"The cumulative incidence of  BSI"}]}]}
>```
>%%
>*%%PREFIX%%nt-related complication of  HCT,%%HIGHLIGHT%% ==bloodstream infections  (BSIs)  are  also  an  important  cause  of   treatment-related  morbidity  and  mortality  in  patients  undergoing allo-HCT.== %%POSTFIX%%The cumulative incidence of  BSI*
>%%LINK%%[[#^jci4zixtnmj|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^jci4zixtnmj


>%%
>```annotation-json
>{"created":"2022-08-08T08:46:19.185Z","updated":"2022-08-08T08:46:19.185Z","document":{"title":"jciinsight-7-154344.pdf","link":[{"href":"urn:x-pdf:8d2ac365139147c193ac91cb106cc20a"},{"href":"vault:/hematology-theroy/papers/jciinsight-7-154344.pdf"}],"documentFingerprint":"8d2ac365139147c193ac91cb106cc20a"},"uri":"vault:/hematology-theroy/papers/jciinsight-7-154344.pdf","target":[{"source":"vault:/hematology-theroy/papers/jciinsight-7-154344.pdf","selector":[{"type":"TextPositionSelector","start":8196,"end":8294},{"type":"TextQuoteSelector","exact":"GD  has  been  explored  in  the  granulocytopenic  population  as  a  strategy  to  reduce  BSI  ","prefix":"erapy for acute leukemia (21).  ","suffix":"(22),  in  patients in intensive"}]}]}
>```
>%%
>*%%PREFIX%%erapy for acute leukemia (21).%%HIGHLIGHT%% ==GD  has  been  explored  in  the  granulocytopenic  population  as  a  strategy  to  reduce  BSI== %%POSTFIX%%(22),  in  patients in intensive*
>%%LINK%%[[#^qxbupirpu|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^qxbupirpu


>%%
>```annotation-json
>{"created":"2022-08-08T08:49:22.464Z","updated":"2022-08-08T08:49:22.464Z","document":{"title":"jciinsight-7-154344.pdf","link":[{"href":"urn:x-pdf:8d2ac365139147c193ac91cb106cc20a"},{"href":"vault:/hematology-theroy/papers/jciinsight-7-154344.pdf"}],"documentFingerprint":"8d2ac365139147c193ac91cb106cc20a"},"uri":"vault:/hematology-theroy/papers/jciinsight-7-154344.pdf","target":[{"source":"vault:/hematology-theroy/papers/jciinsight-7-154344.pdf","selector":[{"type":"TextPositionSelector","start":8671,"end":8914},{"type":"TextQuoteSelector","exact":"BSIs in HCT patients are the consequence of  infectious pathogens entering the bloodstream through indwelling catheters, breakdown in the skin, and mucosal barrier injury (MBI) secondary to conditioning chemotherapy and resulting neutropenia. ","prefix":"n Gram-negative bacteremia (24).","suffix":"Changes in the abundance of  MBI"}]}]}
>```
>%%
>*%%PREFIX%%n Gram-negative bacteremia (24).%%HIGHLIGHT%% ==BSIs in HCT patients are the consequence of  infectious pathogens entering the bloodstream through indwelling catheters, breakdown in the skin, and mucosal barrier injury (MBI) secondary to conditioning chemotherapy and resulting neutropenia.== %%POSTFIX%%Changes in the abundance of  MBI*
>%%LINK%%[[#^b6cd0f6wtin|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^b6cd0f6wtin


>%%
>```annotation-json
>{"created":"2022-08-08T08:49:57.240Z","updated":"2022-08-08T08:49:57.240Z","document":{"title":"jciinsight-7-154344.pdf","link":[{"href":"urn:x-pdf:8d2ac365139147c193ac91cb106cc20a"},{"href":"vault:/hematology-theroy/papers/jciinsight-7-154344.pdf"}],"documentFingerprint":"8d2ac365139147c193ac91cb106cc20a"},"uri":"vault:/hematology-theroy/papers/jciinsight-7-154344.pdf","target":[{"source":"vault:/hematology-theroy/papers/jciinsight-7-154344.pdf","selector":[{"type":"TextPositionSelector","start":9468,"end":9739},{"type":"TextQuoteSelector","exact":",  randomized  study  of   GD  using  oral,  nonab-sorbable  antibiotics  (vancomycin  and  polymyxin  B)  to  assess  the  impact  of   GD  on  the  gut  microbiome   composition  and  diversity,  with  secondary  outcomes  including  aGVHD  and  immune  reconstitution.","prefix":"eve  is  the  first  prospective","suffix":"  GD  with  vancomycin-polymyxin"}]}]}
>```
>%%
>*%%PREFIX%%eve  is  the  first  prospective%%HIGHLIGHT%% ==,  randomized  study  of   GD  using  oral,  nonab-sorbable  antibiotics  (vancomycin  and  polymyxin  B)  to  assess  the  impact  of   GD  on  the  gut  microbiome   composition  and  diversity,  with  secondary  outcomes  including  aGVHD  and  immune  reconstitution.== %%POSTFIX%%GD  with  vancomycin-polymyxin*
>%%LINK%%[[#^oqlmah604ff|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^oqlmah604ff


>%%
>```annotation-json
>{"created":"2022-08-08T08:50:59.889Z","updated":"2022-08-08T08:50:59.889Z","document":{"title":"jciinsight-7-154344.pdf","link":[{"href":"urn:x-pdf:8d2ac365139147c193ac91cb106cc20a"},{"href":"vault:/hematology-theroy/papers/jciinsight-7-154344.pdf"}],"documentFingerprint":"8d2ac365139147c193ac91cb106cc20a"},"uri":"vault:/hematology-theroy/papers/jciinsight-7-154344.pdf","target":[{"source":"vault:/hematology-theroy/papers/jciinsight-7-154344.pdf","selector":[{"type":"TextPositionSelector","start":10729,"end":10790},{"type":"TextQuoteSelector","exact":"Patient characteristics are similar between the 2 study arms.","prefix":"0.1172/jci.insight.154344Results","suffix":" Twenty patients undergoing allo"}]}]}
>```
>%%
>*%%PREFIX%%0.1172/jci.insight.154344Results%%HIGHLIGHT%% ==Patient characteristics are similar between the 2 study arms.== %%POSTFIX%%Twenty patients undergoing allo*
>%%LINK%%[[#^eqvnphk2i45|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^eqvnphk2i45


>%%
>```annotation-json
>{"created":"2022-08-08T08:51:59.537Z","updated":"2022-08-08T08:51:59.537Z","document":{"title":"jciinsight-7-154344.pdf","link":[{"href":"urn:x-pdf:8d2ac365139147c193ac91cb106cc20a"},{"href":"vault:/hematology-theroy/papers/jciinsight-7-154344.pdf"}],"documentFingerprint":"8d2ac365139147c193ac91cb106cc20a"},"uri":"vault:/hematology-theroy/papers/jciinsight-7-154344.pdf","target":[{"source":"vault:/hematology-theroy/papers/jciinsight-7-154344.pdf","selector":[{"type":"TextPositionSelector","start":13244,"end":13593},{"type":"TextQuoteSelector","exact":"To  determine  if   GD  altered  diversity  of   the  gut  microbiota,  we  focused  on  the  primary  endpoint  of   Shannon diversity at 2 weeks after HCT. At this time point, stool specimens likely reflect changes induced by the conditioning regimen and GD in the GD arm, are collected prior to the development of  inflamma-tion  and  aGVHD  (33)","prefix":"BI) GenBank as of  January 2020.","suffix":",  and  usually  precede  the  u"}]}]}
>```
>%%
>*%%PREFIX%%BI) GenBank as of  January 2020.%%HIGHLIGHT%% ==To  determine  if   GD  altered  diversity  of   the  gut  microbiota,  we  focused  on  the  primary  endpoint  of   Shannon diversity at 2 weeks after HCT. At this time point, stool specimens likely reflect changes induced by the conditioning regimen and GD in the GD arm, are collected prior to the development of  inflamma-tion  and  aGVHD  (33)== %%POSTFIX%%,  and  usually  precede  the  u*
>%%LINK%%[[#^w1ohlgclg7i|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^w1ohlgclg7i


>%%
>```annotation-json
>{"created":"2022-08-08T08:53:28.169Z","updated":"2022-08-08T08:53:28.169Z","document":{"title":"jciinsight-7-154344.pdf","link":[{"href":"urn:x-pdf:8d2ac365139147c193ac91cb106cc20a"},{"href":"vault:/hematology-theroy/papers/jciinsight-7-154344.pdf"}],"documentFingerprint":"8d2ac365139147c193ac91cb106cc20a"},"uri":"vault:/hematology-theroy/papers/jciinsight-7-154344.pdf","target":[{"source":"vault:/hematology-theroy/papers/jciinsight-7-154344.pdf","selector":[{"type":"TextPositionSelector","start":15723,"end":15801},{"type":"TextQuoteSelector","exact":"No difference in cumulative exposure to antibiotics between GD and no-GD arms.","prefix":"t microbiota between the 2 arms.","suffix":" We sought to interrogate why gu"}]}]}
>```
>%%
>*%%PREFIX%%t microbiota between the 2 arms.%%HIGHLIGHT%% ==No difference in cumulative exposure to antibiotics between GD and no-GD arms.== %%POSTFIX%%We sought to interrogate why gu*
>%%LINK%%[[#^itt9e17ymug|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^itt9e17ymug


>%%
>```annotation-json
>{"created":"2022-08-08T08:54:39.599Z","text":"假设","updated":"2022-08-08T08:54:39.599Z","document":{"title":"jciinsight-7-154344.pdf","link":[{"href":"urn:x-pdf:8d2ac365139147c193ac91cb106cc20a"},{"href":"vault:/hematology-theroy/papers/jciinsight-7-154344.pdf"}],"documentFingerprint":"8d2ac365139147c193ac91cb106cc20a"},"uri":"vault:/hematology-theroy/papers/jciinsight-7-154344.pdf","target":[{"source":"vault:/hematology-theroy/papers/jciinsight-7-154344.pdf","selector":[{"type":"TextPositionSelector","start":16611,"end":16624},{"type":"TextQuoteSelector","exact":"  postulated ","prefix":"tion  of   these  pathogens,  we","suffix":" that  GD  might  be  associated"}]}]}
>```
>%%
>*%%PREFIX%%tion  of   these  pathogens,  we%%HIGHLIGHT%% ==postulated== %%POSTFIX%%that  GD  might  be  associated*
>%%LINK%%[[#^iet6iows2vh|show annotation]]
>%%COMMENT%%
>假设
>%%TAGS%%
>
^iet6iows2vh


>%%
>```annotation-json
>{"created":"2022-08-08T08:55:05.487Z","updated":"2022-08-08T08:55:05.487Z","document":{"title":"jciinsight-7-154344.pdf","link":[{"href":"urn:x-pdf:8d2ac365139147c193ac91cb106cc20a"},{"href":"vault:/hematology-theroy/papers/jciinsight-7-154344.pdf"}],"documentFingerprint":"8d2ac365139147c193ac91cb106cc20a"},"uri":"vault:/hematology-theroy/papers/jciinsight-7-154344.pdf","target":[{"source":"vault:/hematology-theroy/papers/jciinsight-7-154344.pdf","selector":[{"type":"TextPositionSelector","start":16837,"end":16842},{"type":"TextQuoteSelector","exact":"arms,","prefix":"  antibiotics  between  the  2  ","suffix":"  we  analyzed  the  clinical  r"}]}]}
>```
>%%
>*%%PREFIX%%antibiotics  between  the  2%%HIGHLIGHT%% ==arms,== %%POSTFIX%%we  analyzed  the  clinical  r*
>%%LINK%%[[#^d2g37yy9gys|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^d2g37yy9gys


>%%
>```annotation-json
>{"created":"2022-08-08T08:55:39.059Z","updated":"2022-08-08T08:55:39.059Z","document":{"title":"jciinsight-7-154344.pdf","link":[{"href":"urn:x-pdf:8d2ac365139147c193ac91cb106cc20a"},{"href":"vault:/hematology-theroy/papers/jciinsight-7-154344.pdf"}],"documentFingerprint":"8d2ac365139147c193ac91cb106cc20a"},"uri":"vault:/hematology-theroy/papers/jciinsight-7-154344.pdf","target":[{"source":"vault:/hematology-theroy/papers/jciinsight-7-154344.pdf","selector":[{"type":"TextPositionSelector","start":16844,"end":17087},{"type":"TextQuoteSelector","exact":"we  analyzed  the  clinical  records  based  on  individual  antibiotics,  class  of   antibiotics,  and  clinical  indication  including  broad-spectrum  antibiotics  with  anaer-obic  coverage  (e.g.,  piperacillin-tazobactam,  meropenem).  ","prefix":"iotics  between  the  2  arms,  ","suffix":"We  found  that  the  duration  "}]}]}
>```
>%%
>*%%PREFIX%%iotics  between  the  2  arms,%%HIGHLIGHT%% ==we  analyzed  the  clinical  records  based  on  individual  antibiotics,  class  of   antibiotics,  and  clinical  indication  including  broad-spectrum  antibiotics  with  anaer-obic  coverage  (e.g.,  piperacillin-tazobactam,  meropenem).== %%POSTFIX%%We  found  that  the  duration*
>%%LINK%%[[#^mmngtpm85ek|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^mmngtpm85ek


>%%
>```annotation-json
>{"created":"2022-08-08T08:56:03.723Z","updated":"2022-08-08T08:56:03.723Z","document":{"title":"jciinsight-7-154344.pdf","link":[{"href":"urn:x-pdf:8d2ac365139147c193ac91cb106cc20a"},{"href":"vault:/hematology-theroy/papers/jciinsight-7-154344.pdf"}],"documentFingerprint":"8d2ac365139147c193ac91cb106cc20a"},"uri":"vault:/hematology-theroy/papers/jciinsight-7-154344.pdf","target":[{"source":"vault:/hematology-theroy/papers/jciinsight-7-154344.pdf","selector":[{"type":"TextPositionSelector","start":17545,"end":17588},{"type":"TextQuoteSelector","exact":"Comparison of  secondary clinical outcomes.","prefix":"emic broad-spectrum antibiotics.","suffix":" The prespecified secondary outc"}]}]}
>```
>%%
>*%%PREFIX%%emic broad-spectrum antibiotics.%%HIGHLIGHT%% ==Comparison of  secondary clinical outcomes.== %%POSTFIX%%The prespecified secondary outc*
>%%LINK%%[[#^59tw1t341pw|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^59tw1t341pw


>%%
>```annotation-json
>{"created":"2022-08-08T08:58:20.767Z","updated":"2022-08-08T08:58:20.767Z","document":{"title":"jciinsight-7-154344.pdf","link":[{"href":"urn:x-pdf:8d2ac365139147c193ac91cb106cc20a"},{"href":"vault:/hematology-theroy/papers/jciinsight-7-154344.pdf"}],"documentFingerprint":"8d2ac365139147c193ac91cb106cc20a"},"uri":"vault:/hematology-theroy/papers/jciinsight-7-154344.pdf","target":[{"source":"vault:/hematology-theroy/papers/jciinsight-7-154344.pdf","selector":[{"type":"TextPositionSelector","start":23467,"end":23481},{"type":"TextQuoteSelector","exact":"Study design. ","prefix":"upplemental Figure 4).Figure 2. ","suffix":"Twenty patients undergoing allo-"}]}]}
>```
>%%
>*%%PREFIX%%upplemental Figure 4).Figure 2.%%HIGHLIGHT%% ==Study design.== %%POSTFIX%%Twenty patients undergoing allo-*
>%%LINK%%[[#^b6ai771rayv|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^b6ai771rayv


>%%
>```annotation-json
>{"created":"2022-08-08T10:29:51.821Z","updated":"2022-08-08T10:29:51.821Z","document":{"title":"jciinsight-7-154344.pdf","link":[{"href":"urn:x-pdf:8d2ac365139147c193ac91cb106cc20a"},{"href":"vault:/hematology-theroy/papers/jciinsight-7-154344.pdf"}],"documentFingerprint":"8d2ac365139147c193ac91cb106cc20a"},"uri":"vault:/hematology-theroy/papers/jciinsight-7-154344.pdf","target":[{"source":"vault:/hematology-theroy/papers/jciinsight-7-154344.pdf","selector":[{"type":"TextPositionSelector","start":19529,"end":20946},{"type":"TextQuoteSelector","exact":"  The  following  analyses  of   T  cell  reconstitution  revealed  similar  outcomes  in both groups: median CD4+ T cell count at 3 months after HCT (126.5 in GD arm vs. 182.1 cells/μL  in  no-GD  arm;  P  =  0.24;  Figure  4A);  median  CD4+  T  cell  count  at  6  months  after  HCT  (median,   206.5 in GD arm vs. 248.2 cells/μL in no-GD arm; P = 0.70; Figure 4A); ratio of  regulatory T cells to conventional T cells (Treg/Tcon) in the 12 months post-HCT (Figure 4B); and naive T cell fraction within CD4+ Tcon (Figure 4D). Taken together, these findings suggest that GD does not adversely affect thymic function. Recovery of  CD8+ T cells and natural killer cells was similar between the study arms (Figure 4, C and F, respectively). CD19+ B cell concentration at 12 months was a median of  903.5 cells/μL (IQR, 814.0–984.8) in the GD arm compared with a median of  223.9 cells/μL (IQR, 190.1–333.3) in the no-GD arm (uncorrected P = 0.016; not significant after a stringent Bonferroni-adjusted α level of  0.0045 given 11 biomarkers were tested) (Figure 4E). Of  note, none of  the patients in the no-GD arm received rituximab as  part  of   their  conditioning  regimens  or  as  part  of   posttransplant  therapy.  While  it  is  difficult  to  draw  conclusions from this small study, future, larger studies may further illuminate if  and how immune recon-stitution is influenced by GD and the microbiota.","prefix":" patients  with  graft  failure.","suffix":"Incidence of  BSI. In an explora"}]}]}
>```
>%%
>*%%PREFIX%%patients  with  graft  failure.%%HIGHLIGHT%% ==The  following  analyses  of   T  cell  reconstitution  revealed  similar  outcomes  in both groups: median CD4+ T cell count at 3 months after HCT (126.5 in GD arm vs. 182.1 cells/μL  in  no-GD  arm;  P  =  0.24;  Figure  4A);  median  CD4+  T  cell  count  at  6  months  after  HCT  (median,   206.5 in GD arm vs. 248.2 cells/μL in no-GD arm; P = 0.70; Figure 4A); ratio of  regulatory T cells to conventional T cells (Treg/Tcon) in the 12 months post-HCT (Figure 4B); and naive T cell fraction within CD4+ Tcon (Figure 4D). Taken together, these findings suggest that GD does not adversely affect thymic function. Recovery of  CD8+ T cells and natural killer cells was similar between the study arms (Figure 4, C and F, respectively). CD19+ B cell concentration at 12 months was a median of  903.5 cells/μL (IQR, 814.0–984.8) in the GD arm compared with a median of  223.9 cells/μL (IQR, 190.1–333.3) in the no-GD arm (uncorrected P = 0.016; not significant after a stringent Bonferroni-adjusted α level of  0.0045 given 11 biomarkers were tested) (Figure 4E). Of  note, none of  the patients in the no-GD arm received rituximab as  part  of   their  conditioning  regimens  or  as  part  of   posttransplant  therapy.  While  it  is  difficult  to  draw  conclusions from this small study, future, larger studies may further illuminate if  and how immune recon-stitution is influenced by GD and the microbiota.== %%POSTFIX%%Incidence of  BSI. In an explora*
>%%LINK%%[[#^jr9qotuol6g|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^jr9qotuol6g


>%%
>```annotation-json
>{"created":"2022-08-08T10:38:41.818Z","updated":"2022-08-08T10:38:41.818Z","document":{"title":"jciinsight-7-154344.pdf","link":[{"href":"urn:x-pdf:8d2ac365139147c193ac91cb106cc20a"},{"href":"vault:/hematology-theroy/papers/jciinsight-7-154344.pdf"}],"documentFingerprint":"8d2ac365139147c193ac91cb106cc20a"},"uri":"vault:/hematology-theroy/papers/jciinsight-7-154344.pdf","target":[{"source":"vault:/hematology-theroy/papers/jciinsight-7-154344.pdf","selector":[{"type":"TextPositionSelector","start":26083,"end":26235},{"type":"TextQuoteSelector","exact":" carry out this strain analysis, we used inStrain (30), a tool that can account for  multiple  strain  populations  in  metagenomic  sequencing  data.  ","prefix":"ing pathogens within the gut. To","suffix":"Specifically,  the  population  "}]}]}
>```
>%%
>*%%PREFIX%%ing pathogens within the gut. To%%HIGHLIGHT%% ==carry out this strain analysis, we used inStrain (30), a tool that can account for  multiple  strain  populations  in  metagenomic  sequencing  data.== %%POSTFIX%%Specifically,  the  population*
>%%LINK%%[[#^pra7zkedk4k|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^pra7zkedk4k


>%%
>```annotation-json
>{"created":"2022-08-08T10:40:24.873Z","updated":"2022-08-08T10:40:24.873Z","document":{"title":"jciinsight-7-154344.pdf","link":[{"href":"urn:x-pdf:8d2ac365139147c193ac91cb106cc20a"},{"href":"vault:/hematology-theroy/papers/jciinsight-7-154344.pdf"}],"documentFingerprint":"8d2ac365139147c193ac91cb106cc20a"},"uri":"vault:/hematology-theroy/papers/jciinsight-7-154344.pdf","target":[{"source":"vault:/hematology-theroy/papers/jciinsight-7-154344.pdf","selector":[{"type":"TextPositionSelector","start":29147,"end":29234},{"type":"TextQuoteSelector","exact":", no-GD patient C04 had 2 independent Staphylococcus aureus BSIs on day +5 and day +94 ","prefix":"ble cases individually (Table 3)","suffix":"(Figure 6A). The S. aureus in th"}]}]}
>```
>%%
>*%%PREFIX%%ble cases individually (Table 3)%%HIGHLIGHT%% ==, no-GD patient C04 had 2 independent Staphylococcus aureus BSIs on day +5 and day +94== %%POSTFIX%%(Figure 6A). The S. aureus in th*
>%%LINK%%[[#^5stugracho|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^5stugracho


>%%
>```annotation-json
>{"created":"2022-08-08T10:41:58.215Z","updated":"2022-08-08T10:41:58.215Z","document":{"title":"jciinsight-7-154344.pdf","link":[{"href":"urn:x-pdf:8d2ac365139147c193ac91cb106cc20a"},{"href":"vault:/hematology-theroy/papers/jciinsight-7-154344.pdf"}],"documentFingerprint":"8d2ac365139147c193ac91cb106cc20a"},"uri":"vault:/hematology-theroy/papers/jciinsight-7-154344.pdf","target":[{"source":"vault:/hematology-theroy/papers/jciinsight-7-154344.pdf","selector":[{"type":"TextPositionSelector","start":42825,"end":42892},{"type":"TextQuoteSelector","exact":"Cumulative incidence of BSI during the first 100 days of transplant","prefix":"tistical significance Figure 5. ","suffix":". Patients are separated by trea"}]}]}
>```
>%%
>*%%PREFIX%%tistical significance Figure 5.%%HIGHLIGHT%% ==Cumulative incidence of BSI during the first 100 days of transplant== %%POSTFIX%%. Patients are separated by trea*
>%%LINK%%[[#^g4pkfbnaygm|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^g4pkfbnaygm


>%%
>```annotation-json
>{"created":"2022-08-08T10:50:25.637Z","updated":"2022-08-08T10:50:25.637Z","document":{"title":"jciinsight-7-154344.pdf","link":[{"href":"urn:x-pdf:8d2ac365139147c193ac91cb106cc20a"},{"href":"vault:/hematology-theroy/papers/jciinsight-7-154344.pdf"}],"documentFingerprint":"8d2ac365139147c193ac91cb106cc20a"},"uri":"vault:/hematology-theroy/papers/jciinsight-7-154344.pdf","target":[{"source":"vault:/hematology-theroy/papers/jciinsight-7-154344.pdf","selector":[{"type":"TextPositionSelector","start":39838,"end":40813},{"type":"TextQuoteSelector","exact":"ased on prior studies suggesting interactions between the gut microbiota and development of  circulat-ing immune cells, we examined immune reconstitution of  T and B cell subsets over the first year post-HCT. Although the reconstitution of  T cell and B cell subsets was similar between the study arms after a Bonfer-roni correction, there was an interesting trend in the absolute CD19+ B cell count at 12 months between the arms (Figure 4E). This trend cannot be explained by in vivo depletion as none of  the patients in the no-GD arm received rituximab after HCT. Several reports demonstrate extensive crosstalk between the microbiota and B cell diversity (40–42) and that early B lineage development in mice is influenced by the gut micro-biome  (43).  While  it  is  difficult  to  draw  inferences  with  the  small  numbers  here,  an  analysis  of   immune  reconstitution and potential implications for infection risk should be fully characterized in a larger study.","prefix":"he risk of  grade III–IV aGVHD.B","suffix":"While  the  impact  of   GD  on "}]}]}
>```
>%%
>*%%PREFIX%%he risk of  grade III–IV aGVHD.B%%HIGHLIGHT%% ==ased on prior studies suggesting interactions between the gut microbiota and development of  circulat-ing immune cells, we examined immune reconstitution of  T and B cell subsets over the first year post-HCT. Although the reconstitution of  T cell and B cell subsets was similar between the study arms after a Bonfer-roni correction, there was an interesting trend in the absolute CD19+ B cell count at 12 months between the arms (Figure 4E). This trend cannot be explained by in vivo depletion as none of  the patients in the no-GD arm received rituximab after HCT. Several reports demonstrate extensive crosstalk between the microbiota and B cell diversity (40–42) and that early B lineage development in mice is influenced by the gut micro-biome  (43).  While  it  is  difficult  to  draw  inferences  with  the  small  numbers  here,  an  analysis  of   immune  reconstitution and potential implications for infection risk should be fully characterized in a larger study.== %%POSTFIX%%While  the  impact  of   GD  on*
>%%LINK%%[[#^67esgjmxxzw|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^67esgjmxxzw
